AAA
BBIO icon

Affinity Asset Advisors’s BridgeBio Pharma BBIO Stock Holding History

Affinity Asset Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-376,000
Closed -$6.47M – 83
2023
Q2 		$6.47M Sell
376,000
-13,800
-4% -$208K 2.26% 15
2023
Q1 		$6.46M Buy
+389,800
New +$4.55M 2.13% 16

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Affinity Asset Advisors's BBIO Position: Q2 2026 in Review

Affinity Asset Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 150,000 shares — an estimated $11.1M sold.

Affinity Asset Advisors first reported a position in BBIO in Q4 2020 and held it in 18 quarters. The position peaked at $35.6M in Q1 2021. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Affinity Asset Advisors reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Affinity Asset Advisors sold 150,000 BridgeBio Pharma shares in Q2 2026, an estimated $11.1M.
  • Affinity Asset Advisors first reported a position in BridgeBio Pharma in Q4 2020 and held it in 18 quarters.
  • Affinity Asset Advisors's BridgeBio Pharma position peaked at $35.6M in Q1 2021.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.